Treats pain of osteoarthritis of the knee(s). ANDA 208198, held by Amneal. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 208198 (Diclofenac Sodium), held by Amneal, was first approved by FDA on Aug 18, 2022, with 1 approved supplement and 0 published complete response letters.
Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 18, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium2% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 18, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters